Y
Yu Yao
Researcher at Fudan University
Publications - 68
Citations - 2928
Yu Yao is an academic researcher from Fudan University. The author has contributed to research in topics: Glioma & Immunotherapy. The author has an hindex of 24, co-authored 68 publications receiving 2207 citations. Previous affiliations of Yu Yao include Mongolian National University.
Papers
More filters
Journal ArticleDOI
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway
TL;DR: Clinical trials with mAbs blockading the PD-1/PD-L1 pathway have shown impressive response rates in patients, particularly for melanoma, non-small-cell lung cancer (NSCLC), renal cell carcinoma (RCC), and bladder cancer.
Journal ArticleDOI
CGCG clinical practice guidelines for the management of adult diffuse gliomas
Tao Jiang,Do-Hyun Nam,Zvi Ram,Wai Sang Poon,Jiguang Wang,Damdindorj Boldbaatar,Ying Mao,Wenbin Ma,Qing Mao,Yongping You,Chuanlu Jiang,Xuejun Yang,Chunsheng Kang,Xiaoguang Qiu,Wenbin Li,Shaowu Li,Ling Chen,Xuejun Li,Zhixiong Liu,Weimin Wang,Hongmin Bai,Yu Yao,Shouwei Li,Anhua Wu,Ke Sai,Guilin Li,Kun Yao,Xinting Wei,Xianzhi Liu,Zhiwen Zhang,Yiwu Dai,Sheng-Qing Lv,Liang Wang,Zhixiong Lin,Jun Dong,Guozheng Xu,Xiaodong Ma,Wei Zhang,Chuanbao Zhang,Baoshi Chen,Gan You,Yongzhi Wang,Yinyan Wang,Zhaoshi Bao,Pei Yang,Xing Fan,Xing Liu,Zheng Zhao,Zheng Wang,Yiming Li,Zhiliang Wang,Guanzhang Li,Shengyu Fang,Lianwang Li,Yanwei Liu,Shuai Liu,Xia Shan,Yu-Qing Liu,Ruichao Chai,Huimin Hu,Jing Chen,Wei Yan,Jinquan Cai,Hongjun Wang,Lingchao Chen,Yuan Yang,Yu Wang,Lei Han,Qixue Wang +68 more
TL;DR: The recommendations will provide a framework and assurance for the strategy of diagnostic and therapeutic measures to reduce complications from unnecessary treatment and cost and should serve as an application for all professionals involved in the management of patients with adult diffuse glioma and also as a source of knowledge for insurance companies and other institutionsinvolved in the cost regulation of cancer care in China.
Journal ArticleDOI
Adult IDH wild-type lower-grade gliomas should be further stratified.
Abudumijit Aibaidula,Aden Ka-Yin Chan,Zhifeng Shi,Yanxi Li,Rui-qi Zhang,Rui Ryan Yang,Kay Ka-Wai Li,Nellie Yuk Fei Chung,Yu Yao,Liangfu Zhou,Jinsong Wu,Hong Chen,Ho Keung Ng +12 more
TL;DR: Adult IDH wild-type lower-grade gliomas are prognostically heterogeneous and do not have uniformly poor prognosis.
Journal ArticleDOI
B7-H4(B7x)–Mediated Cross-talk between Glioma-Initiating Cells and Macrophages via the IL6/JAK/STAT3 Pathway Lead to Poor Prognosis in Glioma Patients
Yu Yao,Hongxing Ye,Zengxin Qi,Lian-Jie Mo,Qi Yue,Aparajita Baral,Dave S.B. Hoon,Juan Carlos Vera,John D. Heiss,Clark C. Chen,Wei Hua,Jianmin Zhang,Kunlin Jin,Yin Wang,Xingxing Zang,Ying Mao,Liangfu Zhou +16 more
TL;DR: B7-H4 activation on Mϕs/microglia in the microenvironment of gliomas is identified as an important immunosuppressive event blocking effective T-cell immune responses.
Journal ArticleDOI
TERT promoter mutations contribute to subset prognostication of lower-grade gliomas
Aden Ka-Yin Chan,Yu Yao,Zhen-Yu Zhang,Nellie Yuk Fei Chung,Joseph Shu Ming Liu,Kay Ka Wai Li,Zhifeng Shi,Danny Tat Ming Chan,Wai Sang Poon,Liangfu Zhou,Ho Keung Ng +10 more
TL;DR: It is indicated that when combined with IDH status, TERT promoter mutation contributes to prognostic subgroups of lower-grade astrocytic tumors or 1p/19q intact lower- grade gliomas and this may further refine future molecular classification of lower toastrocytomas.